<DOC>
	<DOCNO>NCT00189709</DOCNO>
	<brief_summary>To determine efficacy safety micafungin ( FK463 ) versus fluconazole ( Diflucan ) treat patient invasive candidiasis candidaemia</brief_summary>
	<brief_title>Micafungin Versus Fluconazole Treatment Invasive Candidiasis Candidemia</brief_title>
	<detailed_description>Micafungin ( new class antifungal drug ) compare fluconazole ( current standard treatment ) treatment patient serious fungal infection ( invasive candidiasis candidemia ) determine efficacy safety . Patients , male female , age 16 confirmed disease doctor could recruit evaluate .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Patients confirm diagnosis candidemia invasive candidiasis Patients could newly diagnose candidiasis receive 48 hour prior systemic antifungal therapy Inpatients age 16 Patients serious invasive candidiasis whose prognosis consider poor ( life expectancy judge less 5 day ) . Patients severe complication liver Pregnant lactate woman Patients receive least 5 day prior systemic treatment fluconazole echinocandin response . Patients prior antifungal infection require treatment systemic antifungal agent condition candidemia invasive candidiasis .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>micafungin</keyword>
	<keyword>fluconazole</keyword>
	<keyword>invasive candidiasis</keyword>
	<keyword>candidemia</keyword>
</DOC>